Mark A. Goldsmith - Jun 17, 2021 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
President and Chief Executive Officer, Director
Signature
/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith
Stock symbol
RVMD
Transactions as of
Jun 17, 2021
Transactions value $
-$50,670
Form type
4
Date filed
6/22/2021, 05:17 PM
Previous filing
Jun 4, 2021
Next filing
Jul 19, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Sale -$50K -1.47K -2.96% $34.13 48K Jun 17, 2021 Direct F4, F5, F6, F7
transaction RVMD Common Stock Sale -$670 -20 -0.04% $33.50 48K Jun 17, 2021 Direct F4, F6, F7, F8
holding RVMD Common Stock 37K Jun 17, 2021 Trust F1
holding RVMD Common Stock 37K Jun 17, 2021 Trust F2
holding RVMD Common Stock 267K Jun 17, 2021 Trust F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Held by Jonathan Henry Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
F2 Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
F3 Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
F4 Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.
F5 This transaction was executed in multiple trades in prices ranging from $33.44 to $34.43, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F6 Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2021.
F7 Includes 45,000 RSUs.
F8 This transaction was executed in multiple trades in prices ranging from $34.44 to $34.52, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

President and Chief Executive Officer